BACKGROUND: Daptomycin is approved for the treatment of complicated skin and skin-structure infections and Staphylococcus aureus bacteremia. We sought to characterize daptomycin single-dose pharmacokinetics and tolerability in young infants. METHODS: Subjects < 120 days of age with suspected systemic infections were eligible for inclusion. Each subject was given a single 6 mg/kg intravenous dose of daptomycin. An average of 4 postdose concentrations per infant was obtained. RESULTS: Data from 20 infants are presented. Median gestational age at birth and postnatal age were 32 weeks (range: 23, 40) and 3 days (1, 85), respectively. The median area under the concentration curve at 24 hours, volume of distribution, total body clearance and half-life of daptomycin were 262.4 mg×h/L (166.7, 340.2), 0.21 L/kg (0.11, 0.34), 0.021 L/h/kg (0.016, 0.034) and 6.2 hours (3.7, 9.0), respectively. No adverse events related to daptomycin were observed, including changes in creatine phosphokinase concentrations. CONCLUSIONS: Daptomycin clearance in young infants was similar to that in children 2-6 years of age and higher than that observed in adolescents and adults.
BACKGROUND:Daptomycin is approved for the treatment of complicated skin and skin-structure infections and Staphylococcus aureus bacteremia. We sought to characterize daptomycin single-dose pharmacokinetics and tolerability in young infants. METHODS: Subjects < 120 days of age with suspected systemic infections were eligible for inclusion. Each subject was given a single 6 mg/kg intravenous dose of daptomycin. An average of 4 postdose concentrations per infant was obtained. RESULTS: Data from 20 infants are presented. Median gestational age at birth and postnatal age were 32 weeks (range: 23, 40) and 3 days (1, 85), respectively. The median area under the concentration curve at 24 hours, volume of distribution, total body clearance and half-life of daptomycin were 262.4 mg×h/L (166.7, 340.2), 0.21 L/kg (0.11, 0.34), 0.021 L/h/kg (0.016, 0.034) and 6.2 hours (3.7, 9.0), respectively. No adverse events related to daptomycin were observed, including changes in creatine phosphokinase concentrations. CONCLUSIONS: Daptomycin clearance in young infants was similar to that in children 2-6 years of age and higher than that observed in adolescents and adults.
Authors: Barry Dvorchik; Robert D Arbeit; Julia Chung; Susan Liu; William Knebel; Helen Kastrissios Journal: Antimicrob Agents Chemother Date: 2004-08 Impact factor: 5.191
Authors: Susan M Abdel-Rahman; Gurudatt Chandorkar; Ronda L Akins; John S Bradley; Richard F Jacobs; Julie Donovan; David P Benziger Journal: Pediatr Infect Dis J Date: 2011-08 Impact factor: 2.129
Authors: Barbara J Stoll; Nellie Hansen; Avroy A Fanaroff; Linda L Wright; Waldemar A Carlo; Richard A Ehrenkranz; James A Lemons; Edward F Donovan; Ann R Stark; Jon E Tyson; William Oh; Charles R Bauer; Sheldon B Korones; Seetha Shankaran; Abbot R Laptook; David K Stevenson; Lu-Ann Papile; W Kenneth Poole Journal: Pediatrics Date: 2002-08 Impact factor: 7.124
Authors: Robert D Arbeit; Dennis Maki; Francis P Tally; Edward Campanaro; Barry I Eisenstein Journal: Clin Infect Dis Date: 2004-05-20 Impact factor: 9.079
Authors: Sin Yin Lim; Teresa Lewis; Sukyung Woo; Martin Turman; David W A Bourne; Michael E Burton; Pornpimol Rianthavorn Journal: J Pediatr Pharmacol Ther Date: 2021-02-15
Authors: Martyn Gostelow; Daniel Gonzalez; P Brian Smith; Michael Cohen-Wolkowiez Journal: Expert Rev Clin Pharmacol Date: 2014-04-09 Impact factor: 4.108